Organon Enters into a License Agreement with Daré Bioscience to Commercialize Xaciato (clindamycin phosphate vaginal gel) for the Treatment of Bacterial Vaginosis
Shots:
- Daré to receive a $10M up front & is eligible to receive a milestone of ~$182.5M along with royalties. The transaction is expected to be close in Q2’22 while Xaciato is expected to be launched in the US in Q4’22
- Organon to get a license right globally to Xaciato (clindamycin phosphate vaginal gel, 2%). Xaciato is the US FDA-approved product for BV in females aged ≥12yrs. & has received QIDP & FTD from the US FDA for the same indication
- Organon has a global footprint with significant scale, geographic reach & commercial capabilities while Daré focus is to identify & develop a diverse portfolio of differentiated therapies for women's health & well-being, expand treatment options & improve outcomes
Ref: Businesswire | Image: Organon
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
